The Imaging Core of the Program Project Grant Healthy Aging and Senile Dementia (HASD) will provide quantitative imaging results for magnetic resonance imaging (MRI), amyloid positron emission tomography (PET) using [11C]-Pittsburgh Compound B (PiB), and tau PET using [18F]-AV-1451 (T807, flortaucipir) to support the affiliated Projects and Cores. Quantitative MRI measures will include volumetric MRI, quantitative and qualitative evaluations of vascular pathology including white matter hyperintensitites (WMH) and cerebral infarctions and microhemorrhages. Amyloid and tau PET will include summary statistics for standardized regions and voxelwise z-score analyses for overall burden and change over time. Exploratory measures will continue to include resting state functional connectivity MRI (rs-fcMRI), diffusion basis spectrum imaging (DBSI) for neuroinflammation, and arterial spin labelling (ASL) for blood flow using protocols compatible with the Alzheimer Disease Neuroimaging Initiative (ADNI-3) and the Dominantly Inherited Alzheimer Network (DIAN). We will continue to explore new MRI and PET options as these become available, such as alternative PET tracers for tau pathology or synaptic imaging, when relevant to the HASD Projects and Cores. We will also continue to promote sharing of the HASD imaging data through updated releases of the Open Access Series of Imaging Studies (OASIS) project.
Core E: Imaging Project Narrative Alzheimer disease (AD) is preceded by up to two decades of clinically silent brain changes (termed ?preclinical AD?) that ultimately result in declines in memory and thinking. Core E: Imaging proposes to use brain imaging tests to identify individuals with preclinical AD at the cusp of developing clinical symptoms so that these individuals can best be targeted for eventual preventative therapies. We will use advanced imaging tests with magnetic resonance imaging (MRI), and positron emission tomography (PET) to detect AD pathology even before memory symptoms are noted.
|Ibanez, Laura; Dube, Umber; Davis, Albert A et al. (2018) Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease. Front Neurosci 12:230|
|Schultz, Stephanie A; Gordon, Brian A; Mishra, Shruti et al. (2018) Widespread distribution of tauopathy in preclinical Alzheimer's disease. Neurobiol Aging 72:177-185|
|Broce, Iris; Karch, Celeste M; Wen, Natalie et al. (2018) Correction: Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS Med 15:e1002504|
|Javaherian, Kavon; Newman, Brianne M; Weng, Hua et al. (2018) Examining the Complicated Relationship Between Depressive Symptoms and Cognitive Impairment in Preclinical Alzheimer Disease. Alzheimer Dis Assoc Disord :|
|Liao, Fan; Li, Aimin; Xiong, Monica et al. (2018) Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. J Clin Invest 128:2144-2155|
|Jansen, Willemijn J; Ossenkoppele, Rik; Tijms, Betty M et al. (2018) Association of Cerebral Amyloid-? Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry 75:84-95|
|Yan, Qi; Nho, Kwangsik; Del-Aguila, Jorge L et al. (2018) Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. Mol Psychiatry :|
|Islam, Jyoti; Zhang, Yanqing (2018) Brain MRI analysis for Alzheimer's disease diagnosis using an ensemble system of deep convolutional neural networks. Brain Inform 5:2|
|Strain, Jeremy F; Smith, Robert X; Beaumont, Helen et al. (2018) Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. Neurology 91:e313-e318|
|Roe, Catherine M; Ances, Beau M; Head, Denise et al. (2018) Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. Brain 141:3233-3248|
Showing the most recent 10 out of 911 publications